Fecal Calprotectin Test Market, By Assay Type (Enzyme Linked Immunosorbent Assay (ELISA), Enzyme Fluoroimmunoassay, and Quantitative Immune-Chromatography), By Indication (Inflammatory Bowel Disease (IBD) Diagnosis, Colorectal Cancer, Celiac Disease, and others), By End User (Hospitals, Diagnostic Laboratories, Academic and Research Institutes, and others), , By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Nov 2023

Code : CMI5952

Pages :170

Formats :

Excel and PDF

Industry : Clinical Diagnostic

Fecal Calprotectin Test MarketSize and Trends

The global fecal calprotectin test market is projected to reach US$ 276.6 million by 2030, from US$ 122.8 million in 2023, at a CAGR of 12.3% during the forecast period 2023-2030.

The growth of the fecal calprotectin test market is driven by the increasing prevalence of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis. IBD is a chronic condition that causes inflammation of the digestive tract. Fecal calprotectin is a protein that is released by white blood cells in the intestines. It is elevated in people with IBD, making it a useful biomarker for diagnosing and monitoring the disease.

The increasing awareness about IBD and its symptoms is also driving the growth of the fecal calprotectin test market. People are more likely to seek medical attention if they are aware of the symptoms of IBD, which can lead to early diagnosis and treatment.

Fecal Calprotectin Test Market Trends

Increasing adoption of non-invasive diagnostic tools: Non-invasive diagnostic tests, such as the fecal calprotectin test, are gaining popularity across various medical fields. Patients and healthcare providers alike are recognizing the value of non-invasive options that offer accurate and reliable results without the need for invasive procedures. The fecal calprotectin test aligns with this trend, as it provides a non-invasive approach to assessing gastrointestinal inflammation.
Shift toward personalized medicine: The healthcare industry is moving toward personalized medicine, where treatments are tailored to individual patients based on their specific characteristics and needs. In the context of the fecal calprotectin test, this trend involves using calprotectin levels as a biomarker to guide treatment decisions. By monitoring calprotectin levels over time, healthcare providers can customize treatment plans for patients, optimizing therapy and improving patient outcomes.